一个新的开始:omidubicel能否成为下一个可行的替代捐赠来源?
Arpita P Gandhi1, Laura F Newell1, Richard T Maziarz2
1Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Therapeutic advances in hematology
|September 4, 2023
概括
带血液移植 (CBT) 提供了一个替代的供体来源,但面临着挑战. 扩大带血产品Omidubicel在改善移植和降低移植患者感染风险方面表现有前途.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
背景情况:
- 带血液移植 (CBT) 是缺乏匹配捐赠者的患者的重要替代方案.
- 标准CBT的挑战包括延迟移植和由于较低的细胞剂量增加的感染风险.
- 欧米杜比塞尔 (Omidubicel) 是一种体扩展单带血产品,旨在克服这些局限性.
研究的目的:
- 审查带血移植的好处和障碍.
- 讨论奥米杜比塞尔在造血干细胞移植中的进展和潜力.
- 突出奥米杜比塞尔在改善免疫复原和减少感染并发症方面的作用.
主要方法:
- 对omidubicel.com的临床试验数据的审查.
- 对结果的分析,比较标准的CBT与用欧米杜比塞尔增强的CBT.
- 在移植中对人类白细胞抗原 (HLA) 匹配的讨论.
主要成果:
- 在临床试验中,Omidubicel表现出快速移植和改善免疫复合.
- 随着奥米杜比塞尔治疗,观察到感染并发症的减少.
- 奥米杜比塞尔已获得FDA批准,用于增强中性粒细胞的恢复和降低感染风险.
结论:
- 奥米杜比塞尔代表了带血液移植的重大进步.
- 这种扩展带血产品解决了传统CBT的关键局限性,改善了患者的治疗结果.
- 奥米杜比塞尔对恶性和非恶性血液病都有潜力.
更多相关视频
相关概念视频
Bone Marrow Sampling and Transplants
359
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
359
Stem Cell Culture
5.2K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.2K


